• 1
    Aboul-Enein F, Rauschka H, Kornel B, Stadelmann C, Stefferl A, Brück W, Lucchinetti CF, Schmidbauer M, Jellinger K, Lassmann H (2003) Preferential loss of myelin associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J Neuropath Exp Neurol 62:2533.
  • 2
    Adams RD, Kubik CS (1952) The morbid anatomy of the demyelinating diseases. Am J Med 12:510546.
  • 3
    Allen IV, McKeown SR (1979) A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis. J Neurol Sci 41:8191.
  • 4
    Allen  IV,  McQuid  S,  Miradkhur  M,  Nevin  G  (2001) Pathological abnormalities in the normal-appearing white matter in multiple sclerosis. Neurol Sci 22:141144.
  • 5
    Aloisi F, Pujol-Borrell R (2006) Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 6:205217.
  • 6
    Babbe H, Roers A, Waisman A, Lassmann H, Goebels N, Hohlfeld R, Friese M, Schröder R, Deckert M, Schmidt S, Ravid R, Rajewsky K (2000) Clonal expansion of CD8+ T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 192:393404.
  • 7
    Balo J (1928) Encephalitis periaxialis concentrica. Arch Neurol 19:242264.
  • 8
    Barkhof F, Brück W, De-Groot CJ, Bergers E, Hulshof S, Geurts J, Polman CH, Van Der Valk P (2003) Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch Neurol 60:10731981.
  • 9
    Barnett MH, Prineas JW (2004) Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 55:458468.
  • 10
    Bien CG, Bauer J, Deckwerth TL, Wiendl H, Deckert M, Wiestler OD, Schramm J, Elger CE, Lassmann H (2002) Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussen’s encephalitis. Ann Neurol 51:311318.
  • 11
    Bitsch A, Wegener C, Da Costa C, Bunkowski S, Reimers CD, Prange HW, Brück W (1999) Lesion development in Marburg’s type of acute multiple sclerosis: from inflammation to demyelination. Mult Scler 5:138146.
  • 12
    Bo L, Vedeler CA, Nyland HI, Trapp BD, Mork SJ (2003) Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropath Exp Neurol 62:723732.
  • 13
    Bo L, Vedeler CA, Nyland H, Trapp BD, Mork SJ (2003) Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler 9:323331.
  • 14
    Bolanos JP, Almeida A, Stewart V, Peuchen S, Land JM, Clark JB, Heales SJ (1997) Nitric oxide mediated mitochondrial damage in the brain: mechanisms and implication for neurodegenerative diseases. J Neurochem 68:22272240.
  • 15
    Booss J, Esiri MM, Tourtellotte WW, Mason DY (1983) Immunohistological analysis of T lymphocyte subsets in the central nervous system in chronic progressive multiple sclerosis. J Neurol Sci 62:219232.
  • 16
    Brink BP, Veerhuis R, Breij EC, Van Der Valk P, Dijkstra CD, Bo L (2005) The pathology of multiple sclerosis is location dependent: no significant complement activation is detected in purely cortical lesions. J Neuropath Exp Neurol 64:147155.
  • 17
    Cannella B, Raine CS (1995) The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 37:424435.
  • 18
    Charcot JM (1880) Lecons sur les maladies du systeme nerveux faites a la Salpetriere. Tome 1, 4e edn. Bureau du Progrès Médical: V.A. Delahaye et Co.: Paris.
  • 19
    Charles P, Reynolds R, Seilhean D, Rougon G, Aigrot MS, Niezgoda A, Zalc B, Lubetzki C (2002) Re-expression of PSA-NCAM by demyelinated axons: an inhibitor or remyelination in multiple sclerosis? Brain 125:19721979.
  • 20
    Coles AJ, Cox A, Le Page E, Jones J, Trip SA, Deans J, Seaman S, Miller D, Hale G, Waldmann H, Compston DA (2006) The window of therapeutic opportunity in multiple sclerosis. Evidence from monoclonal antibody therapy. J Neurol 253:98108.
  • 21
    Confavreux C, Vukusic S, Moreau T, Adeleine P (2000) Relapses and progression of disability in multiple sclerosis. N Engl J Med 343:14301438.
  • 22
    Confavreux C, Vukusic S, Adeleine P (2003) Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126:770782.
  • 23
    Courville CB (1970) Concentric sclerosis. In: Handbook of Clinical Neurology, Vol. 9. PJVinken, GWBruyn (eds), pp. 437451. North Holland: Amsterdam.
  • 24
    Cree B (2006) Emerging monoclonal antibody therapies for multiple sclerosis. Neurologist 12:171178.
  • 25
    Devic E (1984) Myelite subaigue compliquee de nevrite optique. Bull Med 8:1033.
  • 26
    Dutta R, McDonough J, Yin X, Peterson J, Chang A, Torres T, Gudz T, Macklin WB, Lewis DA, Fox RJ, Rudick R, Mirnics K, Trapp BD (2006) Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis. Ann Neurol 59:478489.
  • 27
    Evangelou N, Konz D, Esiri MM, Smith S, Palace J, Matthews PM (2000) Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis. Brain 123:18451849.
  • 28
    Evangelou N, Konz D, Esiri MM, Smith S, Palace J, Matthews PM (2001) Size-selective neuronal changes in the anterior optic pathways suggest a differential susceptibility to injury in multiple sclerosis. Brain 124:18131820.
  • 29
    Evangelou N, DeLuca GC, Owens T, Esiri MM (2005) Pathological study of spinal cord atrophy in multiple sclerosis suggests limited role of focal lesions. Brain 128:2934.
  • 30
    Felts PA, Woolston AM, Fernando HB, Asquith S, Gregson NA, Mizzi OJ, Smith KJ (2005) Inflammation and primary demyelination induced by the intraspinal injections of lipopolysaccharide. Brain 128:16491666.
  • 31
    Ferguson B, Matyszak MK, Esiri MM, Perry VH (1997) Axonal damage in acute multiple sclerosis lesions. Brain 120:393399.
  • 32
    Flugel A, Berkowicz T, Ritter T, Labeur M, Jenne DE, Li Z, Ellwart JW, Willem M, Lassmann H, Wekerle H (2001) Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis. Immunity 14:547560.
  • 33
    Fraenkel M, Jakob A (1913) Zur Pathologie der multiplen Sklerose mit besonderer Berücksichtigung der akuten Formen. Z Neurol 14:565603.
  • 34
    Friese MA, Fugger L (2005) Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy? Brain 128:17471763.
  • 35
    Frohmann E, Racke MK, Raine CS (2006) Multiple sclerosis—the plaque and its pathogenesis. N Engl J Med 354:942955.
  • 36
    Gay FW, Drye GW, Dick GWA, Esiri MM (1997) The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis: identification and characterization of the primary demyelinating lesion. Brain 120:14611483.
  • 37
    Gold R, Linington C, Lassmann H (2006) Understanding pathogenesis and therapy of multiple sclerosis vial animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129:19531971.
  • 38
    Graumann U, Reynolds R, Steck AJ, Schaeren-Wiemers N (2003) Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol 13:554573.
  • 39
    Hallervorden J (1940) Die zentralen Entmarkungserkrankungen. Dtsch Z Nervenheilk 150:201239.
  • 40
    Hayashi T, Morimoto C, Burks JS, Kerr C, Hauser SL (1988) Dual-label immunocytochemistry of the active multiple sclerosis lesion: major histocompatibility complex and activation antigens. Ann Neurol 24:523531.
  • 41
    Hochmeister S, Grundtner R, Bauer J, Engelhardt B, Lyck R, Gordon G, Korosec T, Kutzelnigg A, Berger J, Bradl M, Bittner RE, Lassmann H (2006) Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis. J Neuropath Exp Neurol 65:855865.
  • 42
    Höftberger R, Aboul-Enein F, Brueck W, Lucchinetti C, Rodriguez M, Schmidbauer M, Jellinger K, Lassmann H (2004) Expression of Major Histocompatibility Complex Class I molecules on the different cell types in multiple sclerosis lesions. Brain Pathol 14:4350.
  • 43
    Hohlfeld R, Wekerle H (2004) Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci USA 101(Suppl. 2):1459914606.
  • 44
    Huang D, Han Y, Rani MR, Glabinski A, Trebst C, Sorensen T, Tani M, Wang J, Chien P, Bryan S, Bielecki B, Zhou ZL, Majmuder S, Ransohoff RM (2000) Chemokines and chemokine receptors in inflammation of the nervous system: manifold roles and exquisite regulation. Immunol Rev 177:5267.
  • 45
    Jellinger K (1969) Einige morphologische Aspekte der Multiplen Sklerose. Wien Z Nervenheilk II(Suppl.):1237.
  • 46
    Keegan M, König F, McClelland R, Brück W, Morales Y, Bitsch A, Panitch H, Lassmann H, Weinshenker B, Rodriguez M, Parisi J, Lucchinetti CF (2005) Relation between humoral pathological changes in multiple sclerosis and response to plasma exchange. Lancet 366:579582.
  • 47
    Kidd T, Barkhof F, McConnell R, Algra PR, Allen IV, Revesz T (1999) Cortical lesions in multiple sclerosis. Brain 122:1726.
  • 48
    Kirk J, Plumb J, Mirakhur M, McQuaid S (2003) Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination. J Pathol 201:319327.
  • 49
    Kornek B, Storch M, Weissert R, Wallstroem E, Stefferl A, Olsson T, Linington C, Schmidbauer M, Lassmann H (2000) Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive and remyelinated lesions. Am J Pathol 157:267276.
  • 50
    Kutzelnigg A, Lassmann H (2006) Cortical demyelination in multiple sclerosis: a substrate for cognitive deficits? J Neurol Sci 245:123126.
  • 51
    Kutzelnigg A, Lucchinetti CF, Stadelmann C, Brück W, Rauschka H, Bergmann M, Schmidbauer M, Parisi J, Lassmann H (2005) Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128:27052712.
  • 52
    Kutzelnigg A, Faber-Rod JC, Bauer J, Lucchinetti CF, Sorensen PS, Laursen H, Stadelmann C, Brück W, Rauschka H, Schmidbauer M, Lassmann H (2007) Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol (in press).
  • 53
    Kwon EE, Prineas JW (1994) Blood brain barrier abnormalities in longstanding multiple sclerosis lesions. An immunohistochemical study. J Neuropath Exp Neurol 53:625636.
  • 54
    Lennon VA, Wingerchuk DN, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker B (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:21062112.
  • 55
    Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202:473477.
  • 56
    Linington C, Bradl M, Lassmann H, Brunner C, Vass K (1988) Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 130:443454.
  • 57
    Linker RA, Maurer M, Gaupp S, Martini R, Holtmann B, Giess R, Rieckmann P, Lassmann H, Toyka KV, Sendtner M, Gold R (2002) CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat Med 8:620624.
  • 58
    Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H (1999) A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 117 cases. Brain 122:22792295.
  • 59
    Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47:707717.
  • 60
    Lucchinetti CF, Mandler R, McGavern D, Brück W, Gleich G, Ransohoff RM, Trebst C, Weinshenker B, Wingerchuck D, Parisi J, Lassmann H (2002) A role for humoral mechanisms in he pathogenesis of Devic’s neuromyelitis optica. Brain 125:14501461.
  • 61
    Lucchinetti CF, Brück W, Lassmann H (2004) Evidence for pathogenetic heterogeneity in multiple sclerosis. Ann Neurol 56:308.
  • 62
    Marburg O (1906) Die sogenannte “akute Multiple Sklerose”. Jahrb Psychiatrie 27:211312.
  • 63
    Meinl E, Krumbholz M, Hohlfeld R (2006) B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production and therapeutic modulation. Ann Neurol 59:880892.
  • 64
    Merkler D, Ernsting T, Kerschensteiner M, Brück W, Stadelmann C (2006) A new focal EAE model of cortical demyelination: MS-like lesions with rapid resolution of inflammation and extensive remyelination. Brain 129:19721983.
  • 65
    Miller DH, Barkhof F, Frank JA, Parker GJ, Thompson AJ (2002) Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 125:16761695.
  • 66
    Moore GR, Neumann PE, Sutuki K, Lijtmaer HN, Traugott U, Raine CS (1985) Balo’s concentric sclerosis: new observations on lesion development. Ann Neurol 17:604611.
  • 67
    Neumann H, Medana I, Bauer J, Lassmann H (2002) Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trend Neurosci 25:313319.
  • 68
    Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker B (2000) Multiple sclerosis. N Engl J Med 343:938952.
  • 69
    Ozawa K, Suchanek G, Breitschopf H, Brück W, Budka H, Jellinger K, Lassmann H (1994) Patterns of oligodendroglia pathology in multiple sclerosis. Brain 117:13111322.
  • 70
    Patrikios P, Stadelmann C, Kutzelnigg A, Rauschka H, Schmidbauer M, Laursen H, Soelberg Sorensen P, Brück W, Lucchinetti C, Lassmann H (2006) Remyelination is extensive in a subset of multiple sclerosis patients. Brain 129:31653172.
  • 71
    Peterson JW, Bo L, Mork S, Chang A, Trapp BD (2001) Transected neurites, apoptotic neurons and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 50:389400.
  • 72
    Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuck DM, Corboy JR, Lennon VA (2006) Neuromyelitis optica brain lesions localized at sites of high aquaporin-4 expression. Arch Neurol 63:964968.
  • 73
    Pomeroy IM, Matthews PM, Frank JA, Jordan EK, Esiri MM (2005) Demyelinated neocortical lesions in marmoset autoimmune encephalomyelitis mimic those in multiple sclerosis. Brain 128:27132721.
  • 74
    Prineas JW, Connell F (1979) Remyelination in multiple sclerosis. Ann Neurol 5:2231.
  • 75
    Prineas JW, Kwon EE, Cho ES, Sharer LR (1984) Continual breakdown and regeneration of myelin in progressive multiple sclerosis plaques. Ann NY Acad Sci 436:1132.
  • 76
    Prineas JW, Kwon EE, Goldenberg PZ, Ilyas AA, Quarles RH, Benjamins JA, Sprinkle TJ (1989) Multiple sclerosis. Oligodendrocyte proliferation and differentiation in fresh lesions. Lab Invest 61:489503.
  • 77
    Prineas JW, Barnard RO, Kwon EE, Sharer LR, Cho ES (1993) Multiple sclerosis: remyelination of nascent lesions. Ann Neurol 33:137151.
  • 78
    Prineas JW, Kwon EE, Cho ES, Sharer LR, Barnett MH, Oleszak EL, Hoffman B, Morgan BP (2001) Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol 50:646657.
  • 79
    Raine CS, Scheinberg L, Waltz JM (1981) Multiple sclerosis: oligodendrocyte survival and proliferation in an active established lesion. Lab Invest 45:534546.
  • 80
    Roemer SF, Parisi JE, Lennon VA, Mandler R, Weinshenker BG, Benarroch E, Pittock SJ, Wingerchuck DM, Lassmann H, Brück W, Lucchinetti CF (2007) Distinct pattern of Aquaporin-4 expression in neuromyelitis optica lesions. Brain (in press).
  • 81
    Schlesinger H (1909) Zur Frage der akuten multiplen Sklerose und der encephalomyelitis disseminata im Kindesalter. Arb Neurol Inst (Wien) 17:410432.
  • 82
    Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F (2004) Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 14:164174.
  • 83
    Stadelmann C, Ludwin S, Tabira T, Guseo A, Lucchinetti CF, Leel-Össy L, Ordinario AT, Brück W, Lassmann H (2005) Tissue preconditioning may explain concentric lesions in Balo’s type of multiple sclerosis. Brain 128:979987.
  • 84
    Storch MK, Piddlesden S, Haltia M, Iivanainen M, Morgan P, Lassmann, H (1998) Multiple sclerosis: in situ evidence for antibody and complement mediated demyelination. Ann Neurol 43:465471.
  • 85
    Stys PK (2005) General mechanisms of axonal damage and its prevention. J Neurol Sci 133:313.
  • 86
    Sun D, Whitaker JN, Huang Z, Liu D, Coleclough C, Wekerle H, Raine CS (2001) Myelin antigen specific CD8+ T cells are encephalitogenic and produce severe disease in C57Bl/6 mice. J Immunol 166:75797587.
  • 87
    Tabira T (1994) Concentric sclerosis Balo. Nippon Rinsho 52:29712975.
  • 88
    Thompson AJ, Kermode AG, Wicks D, MacManus DG, Kendall BE, Kingsley DP, McDonald WI (1991) Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 29:5362.
  • 89
    Thompson AJ, Polman CH, Miller DH, McDonald IW, Brochet B, Filippi M, Montalban X, De Sa J (1997) Primary progressive multiple sclerosis. Brain 120:10851096.
  • 90
    Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278285.
  • 91
    Weinshenker BG, Wingerchuk DM, Vukusic S, Linbo L, Pittock SJ, Lucchinetti CF, Lennon VA (2006) Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 59:566569.
  • 92
    Wingerchuk DM, Weinshenker BG (2003) Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology 60:848853.
  • 93
    Wingerchuck DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66:14851489.
  • 94
    Zamvil SS, Steinman L (2003) Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis. Neuron 38:685688.